SEP 08, 2018 1:54 PM PDT

Protein Associated With ALS Inspires Drug Treatments

WRITTEN BY: Nouran Amin

Neurodegenerative diseases, such as degenerative ataxia or amyotrophic lateral sclerosis (ALS), will progressively cause an affected individual to develop the inability to move and think. Unfortunately, there exists only few treatments. However, findings from a recent research study published in Nature Communications have found potential approaches for developing therapeutic drugs, opening the doors for more treatments.

The researchers, from the University of Utah Health, have identified a protein called ‘Staufen1’ which accumulates in the cells of patients suffering from degenerative ataxia or ALS, also known as Lou Gehrig's disease. "Staufen was first discovered in the fruit fly and has been studied for 30 years, but it had never been connected to anything related to disease," says Stefan Pulst M.D., Dr. Med., chair of Neurology at U of U Health and senior researcher on the study. "This is a novel finding." Removing staufen1 protein from model mice with neurodegenerative diseases was shown to improve the exhibited disease symptoms including motor function.

Credit: Readers Digest

The results suggest that developing drugs that target Staufen1 could have a therapeutic potential in patients. "This is a completely new avenue for thinking about neurodegenerative diseases," explains Pulst. "A protein that had never been known to be involved in neurodegeneration is now a great target for drug treatments."

Previous studies did not see the protein as a problem in neurodegenerative disease until researchers found a relationship between Staufen1 and ataxia, a rare condition causing loss of movement. More specifically, the scientists discovered that Staufen1 binds with another protein called ‘Ataxin2’ which is a risk factor for ALS and responsible for ataxia. Future research will aim on determining whether drugs or other therapeutics that can decrease Staufen1 can be developed to treat other diseases. Additionally, the research “connects Staufen1 to the emerging concept that neurodegenerative diseases are linked to malfunctions in the way cells cope with cellular stress.”

“One implication”, says co-author Daniel Scoles, Ph.D., associate professor of Neurology at U of U Health, “is that Staufen1-targeted therapies could work against a number of disorders in which stress granules emerge, although it remains to be determined whether the aggregates themselves lead to disease. Our results put the stress granule in focus as a structure to target in disease."

Source: University of Utah, Nature Communications

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
NOV 19, 2019
Drug Discovery & Development
NOV 19, 2019
Psychedelic DMT Creates Vivid Waking Dream State in Brain
In a new study, scientists at Imperial College London investigated how powerful psychedelic dimethyltryptamine (DMT) alters the brain’s electrical ac...
NOV 22, 2019
Health & Medicine
NOV 22, 2019
Federal Government Weighs in on Marijuana and Opioid Addiction
The U.S. government is weighing in on the hot topic of whether or not medical marijuana is a successful tool in treating opioid addiction by barring the us...
NOV 25, 2019
Drug Discovery & Development
NOV 25, 2019
Darobactin: Promising New Drug to Combat Antibiotic Resistance
Every year, around 700,000 people are estimated to die from drug-resistant infections thanks to our overuse of antibiotics both in agriculture and medicine...
DEC 16, 2019
Drug Discovery & Development
DEC 16, 2019
IV Treatment for Traumatic Brain Injury
Scientists are now using exosomes intravenously as a method of cell-to-cell technology for treating patients with traumatic brain injury (TBI). They discov...
DEC 20, 2019
Drug Discovery & Development
DEC 20, 2019
Drug Repurposing May Provide Hope for Deadly Childhood Seizure Disorder
The life-threatening and treatment-resistant seizure disorder among children known as the ‘Dravet Syndrome’ may soon have new safe and effectiv...
JAN 04, 2020
Cardiology
JAN 04, 2020
New Protein Therapy Improves Heart Attack Survival Rates
Heart disease is the top killer in the Western world. This is partially because, if one manages to survive an initial heart attack, oftentimes the scar tis...
Loading Comments...